Source MS Trust: A recent review has outlined the progress made so far in understanding the biology of remyelination, what goes wrong in MS, some of the research problems that need to be tackled and the prospect for treatments in the not-too-distant future.
Source MS Trust: A recent review has outlined the progress made so far in understanding the biology of remyelination, what goes wrong in MS, some of the research problems that need to be tackled and the prospect for treatments in the not-too-distant future.
Considerable progress has been made in understanding the biology of remyelination. This has identified potential treatments, such as clemastine, opicinumab and bexarotene which are being tested in clinical trials.
The review shows that a good deal of progress has already been made, although there is still much to be done. The authors finish by identifying questions that further research needs to address in order to build on this work. Read on.
